Sanofi-Aventis and Novartis, the case is closed. For Glaxo-Smith-Kline, not yet. The French state, which had ordered millions of vaccine against H1N1, was canceled last January some of the orders, forcing him to pay compensation to these laboratories.
In all, the French government had ordered 160 million doses of vaccines, including 94 million to Sanofi Pasteur, the vaccines arm of Sanofi-Aventis European leader, at 50 million British Glaxo-Smith-Kline (GSK) and 16 million Swiss Novartis.
While the epidemic of influenza was less concern, the Health Minister, Roselyne Bachelot, has gone back on his feet and set aside 2 million doses from Sanofi-Aventis. Novartis has seen its order reduced by 7 million units, while GSK shipped 32 million in vaccines and less.
- GPs invited to price at 23 euros consultation
- The CAC 40 is approaching the threshold of 3900 points
- The Cac 40 attempts to reconnect with 4000 points
- The CAC 40 seeks to safeguard the 4,000 points
- The Swiss are trying to adapt to the high cost of living